,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,AC136616.3,,ENSG00000278782,,Unmapped,1157687-1240349,Predicted intracellular proteins,Evidence at transcript level,,,,,,,,Tissue enhanced,,"cervix, uterine: 8.6;tonsil: 6.6","breast,small intestine: 5.4",Not detected,,
1,ADAMTSL5,THSD6,ENSG00000185761,ADAMTS like 5,19,1505018-1513604,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA044050,,,Approved,Golgi apparatus,,Mixed,Tissue enhanced,,"cervix, uterine: 29.0",smooth muscle: 17.4,Mixed,,
2,ADRA1D,"ADRA1, ADRA1A, ADRA1R",ENSG00000171873,Adrenoceptor alpha 1D,20,4220631-4249074,"FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA038789,Uncertain,,,,,Mixed,Tissue enhanced,,"cervix, uterine: 4.3;prostate: 4.5",seminal vesicle: 2.6,Cell line enhanced,,BJ: 6.7;CAPAN-2: 3.1;fHDF/TERT166: 3.7
3,ADRA2C,"ADRA2L2, ADRA2RL2, ADRARL2",ENSG00000184160,Adrenoceptor alpha 2C,4,3766348-3768526,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,HPA057688,Uncertain,,,,,Mixed,Tissue enhanced,,"cervix, uterine: 20.9;endometrium: 26.0;seminal vesicle: 26.8",fallopian tube: 7.9,Cell line enhanced,,Hep G2: 9.0;MCF7: 16.8;SCLC-21H: 9.5;SH-SY5Y: 10.3
4,AMY1C,AMY1,ENSG00000187733,"Amylase, alpha 1C (salivary)",1,103750406-103758690,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA045394, HPA045399, HPA046980",Supported,,,,,Not detected,Tissue enhanced,,"cervix, uterine: 33.0;salivary gland: 101.8",pancreas: 26.4,Not detected,,
5,ANGPT4,,ENSG00000101280,Angiopoietin 4,20,869899-916317,"Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"CAB013260, CAB013305",Uncertain,,,,,Not detected,Tissue enhanced,,"cervix, uterine: 5.4",adipose tissue: 2.7,Group enriched,92.0,ASC diff: 23.2;BEWO: 47.4
6,ANKFN1,FLJ38335,ENSG00000153930,Ankyrin repeat and fibronectin type III domain containing 1,17,55882301-56511659,Predicted intracellular proteins,Evidence at protein level,"HPA021566, HPA022538",Uncertain,,,,,Mixed,Tissue enhanced,,"cervix, uterine: 14.3;fallopian tube: 8.5","cerebral cortex,testis: 3.2",Cell line enhanced,,HeLa: 4.8;MOLT-4: 12.3;T-47d: 4.7;U-2197: 4.5
7,ATP6V1C2,"ATP6C2, VMA5",ENSG00000143882,ATPase H+ transporting V1 subunit C2,2,10721649-10785110,"Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA034734, HPA067305",Approved,,Uncertain,Mitochondria,Renal cancer:1.12e-11 (unfavourable),Mixed,Tissue enhanced,,"cervix, uterine: 83.9;epididymis: 99.0;skin: 123.7",placenta: 55.1,Group enriched,9.0,BEWO: 71.4;SK-BR-3: 20.0
8,BMPR1B,"ALK6, CDw293",ENSG00000138696,Bone morphogenetic protein receptor type 1B,4,94757968-95158448,"CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,Endometrial cancer:2.84e-4 (favourable),Tissue enhanced,Tissue enhanced,,"cervix, uterine: 37.2;prostate: 37.0",seminal vesicle: 21.0,Cell line enhanced,,A549: 21.1;SH-SY5Y: 20.1
9,BPIFB1,"bA49G10.6, C20orf114, dJ1187J4.1, LPLUNC1, MGC14597, VEMSGP",ENSG00000125999,BPI fold containing family B member 1,20,33273480-33309878,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA024256,Supported,,,,,Tissue enhanced,Tissue enhanced,,"cervix, uterine: 839.4;stomach: 443.3",lung: 157.3,Cell line enhanced,,CAPAN-2: 2.2;RT4: 1.6;SK-BR-3: 3.1
10,C1orf186,FLJ16052,ENSG00000263961,Chromosome 1 open reading frame 186,1,206037231-206102459,Predicted membrane proteins,Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,"cervix, uterine: 37.8",seminal vesicle: 28.9,Cell line enriched,7.0,HMC-1: 1374.2
11,C6orf15,STG,ENSG00000204542,Chromosome 6 open reading frame 15,6,31111223-31112559,Predicted secreted proteins,Evidence at transcript level,HPA001436,Uncertain,,,,,Mixed,Tissue enhanced,,"cervix, uterine: 2.0",tonsil: 0.8,Group enriched,12.0,RH-30: 3.1;U-2 OS: 1.4
12,CA10,"CA-RPX, CARPX, HUCEP-15",ENSG00000154975,Carbonic anhydrase 10,17,51630313-52160017,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA054825, HPA057837",Supported,,Approved,Vesicles,,Tissue enhanced,Tissue enhanced,,"cerebral cortex: 56.7;cervix, uterine: 32.1",testis: 10.7,Cell line enhanced,,RT4: 1.6;SCLC-21H: 7.3
13,CACNA1G,"Cav3.1, NBR13",ENSG00000006283,Calcium voltage-gated channel subunit alpha1 G,17,50561068-50627474,"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,HPA004714,Uncertain,,,,,Mixed,Tissue enhanced,,"cerebral cortex: 10.5;cervix, uterine: 8.5",endometrium: 5.2,Cell line enhanced,,A549: 8.5;SCLC-21H: 3.3
14,CCDC129,FLJ38344,ENSG00000180347,Coiled-coil domain containing 129,7,31514071-31658720,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA024103,Uncertain,,Uncertain,Nucleoplasm,,Not detected,Tissue enhanced,,"cervix, uterine: 2.6;salivary gland: 2.4",testis: 2.1,Cell line enhanced,,U-2 OS: 1.6
15,CD8B,CD8B1,ENSG00000172116,CD8b molecule,2,86815339-86861924,"CD markers, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB004353, HPA029164",Enhanced,,Supported,Plasma membrane,"Endometrial cancer:7.88e-7 (favourable), Renal cancer:7.11e-6 (unfavourable)",Mixed,Tissue enhanced,,"cervix, uterine: 60.8;lymph node: 39.6",parathyroid gland: 22.7,Cell line enriched,50.0,RPMI-8226: 837.8
16,CDH12,"Br-cadherin, CDHB",ENSG00000154162,Cadherin 12,5,21750673-22853622,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA029325,Uncertain,,Approved,Vesicles,,Mixed,Tissue enhanced,,"cerebral cortex: 3.6;cervix, uterine: 4.5;fallopian tube: 3.5",adrenal gland: 2.2,Group enriched,5.0,PC-3: 2.0;SCLC-21H: 3.7;U-2 OS: 1.3
17,CHAD,SLRR4A,ENSG00000136457,Chondroadherin,17,50464496-50468966,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA018241,Enhanced,,,,"Liver cancer:1.59e-4 (favourable), Breast cancer:7.68e-4 (favourable)",Tissue enhanced,Tissue enhanced,,"cervix, uterine: 31.8",adrenal gland: 13.4,Cell line enhanced,,RT4: 3.4;SCLC-21H: 10.1
18,CHST6,MCDC1,ENSG00000183196,Carbohydrate sulfotransferase 6,16,75472052-75495384,"Disease related genes, Predicted secreted proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,"cervix, uterine: 16.3;duodenum: 10.6;small intestine: 10.9",cerebral cortex: 7.9,Cell line enhanced,,AN3-CA: 10.8;CAPAN-2: 11.4;NTERA-2: 6.2;U-2 OS: 8.0;WM-115: 6.7
19,CHSY3,"CHSY-2, CSS3",ENSG00000198108,Chondroitin sulfate synthase 3,5,129904472-130186634,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA044612,Uncertain,,,,,Mixed,Tissue enhanced,,"cervix, uterine: 7.2",gallbladder: 4.5,Cell line enhanced,,ASC diff: 9.0;ASC TERT1: 8.1;U-138 MG: 14.0
20,CILP,HsT18872,ENSG00000138615,Cartilage intermediate layer protein,15,65194758-65211488,"Disease related genes, Predicted secreted proteins",Evidence at protein level,HPA003195,Uncertain,,,,Thyroid cancer:2.24e-5 (unfavourable),Tissue enhanced,Tissue enhanced,,"cervix, uterine: 67.0;smooth muscle: 70.8",gallbladder: 54.9,Cell line enhanced,,ASC diff: 2.9;ASC TERT1: 1.7;EFO-21: 1.0;HSkMC: 4.7
21,COL14A1,UND,ENSG00000187955,Collagen type XIV alpha 1 chain,8,120059780-120372036,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA023781,Uncertain,,Approved,Vesicles,"Renal cancer:5.79e-5 (unfavourable), Urothelial cancer:1.01e-4 (unfavourable)",Expressed in all,Tissue enhanced,,"cervix, uterine: 278.5",gallbladder: 207.5,Group enriched,7.0,ASC TERT1: 28.1;RH-30: 106.3
22,COL21A1,,ENSG00000124749,Collagen type XXI alpha 1 chain,6,56056590-56394094,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA031212,,,Supported,Cytosol,,Mixed,Tissue enhanced,,"cervix, uterine: 36.7;placenta: 39.0",endometrium: 19.6,Cell line enhanced,,ASC TERT1: 15.7;BEWO: 7.2;HSkMC: 16.7
23,COL3A1,EDS4A,ENSG00000168542,Collagen type III alpha 1 chain,2,188974320-189012746,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA007583, CAB016766, CAB059993",Approved,,,,Renal cancer:3.59e-10 (unfavourable),Expressed in all,Tissue enhanced,,"cervix, uterine: 3796.7;gallbladder: 3334.2;smooth muscle: 3029.8",placenta: 2768.0,Cell line enhanced,,AF22: 1344.2;ASC diff: 1690.4;ASC TERT1: 2979.5;fHDF/TERT166: 1406.5;HHSteC: 1419.6;HSkMC: 2318.4
24,CSF3,"C17orf33, G-CSF, GCSF, MGC45931",ENSG00000108342,Colony stimulating factor 3,17,40015361-40017813,"Cancer-related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Endometrial cancer:8.45e-4 (favourable),Mixed,Tissue enhanced,,"appendix: 19.1;cervix, uterine: 38.2",adipose tissue: 10.3,Cell line enhanced,,BJ hTERT+: 57.2;hTEC/SVTERT24-B: 34.2;U-87 MG: 265.0
25,CTSV,"CTSL2, CTSU",ENSG00000136943,Cathepsin V,9,97029679-97039643,"Enzymes, Predicted secreted proteins",Evidence at protein level,CAB017112,Uncertain,,Approved,Nucleus<br>Nucleoli fibrillar center<br>Plasma membrane<br>Cytosol,"Liver cancer:2.83e-5 (unfavourable), Urothelial cancer:2.39e-4 (unfavourable), Pancreatic cancer:2.87e-4 (unfavourable), Endometrial cancer:8.41e-4 (favourable)",Mixed,Tissue enhanced,,"cervix, uterine: 69.3;skin: 64.2;testis: 131.8",placenta: 25.9,Cell line enriched,7.0,BEWO: 563.7
26,CXCL1,"FSP, GRO1, GROa, MGSA, MGSA-a, NAP-3, SCYB1",ENSG00000163739,C-X-C motif chemokine ligand 1,4,73869393-73871242,"Cancer-related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,"Renal cancer:1.60e-4 (unfavourable), Liver cancer:2.91e-4 (unfavourable), Cervical cancer:7.23e-4 (unfavourable), Breast cancer:7.83e-4 (favourable)",Expressed in all,Tissue enhanced,,"cervix, uterine: 178.6;spleen: 112.8",urinary bladder: 92.0,Group enriched,7.0,BJ hTERT+: 658.8;EFO-21: 1914.4;RPTEC TERT1: 559.0
27,CXCL3,"CINC-2b, GRO3, GROg, MIP-2b, SCYB3",ENSG00000163734,C-X-C motif chemokine ligand 3,4,74036589-74038807,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Cervical cancer:2.33e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,"adipose tissue: 26.9;cervix, uterine: 33.6",appendix: 20.3,Cell line enhanced,,BJ hTERT+: 39.2;hTEC/SVTERT24-B: 75.0;RPTEC TERT1: 32.7
28,CYP4X1,MGC40051,ENSG00000186377,Cytochrome P450 family 4 subfamily X member 1,1,47023568-47050751,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA017661,Approved,,,,,Mixed,Tissue enhanced,,"cervix, uterine: 52.7",breast: 18.7,Cell line enhanced,,CACO-2: 3.6;NTERA-2: 2.0;SCLC-21H: 3.0;T-47d: 8.7
29,DEFB1,"BD1, DEFB-1, DEFB101, HBD-1, HBD1, MGC51822",ENSG00000164825,Defensin beta 1,8,6870575-6878022,"Predicted secreted proteins, Transporters",Evidence at protein level,,,,,,"Renal cancer:1.90e-5 (favourable), Lung cancer:5.62e-4 (unfavourable), Pancreatic cancer:5.94e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,"cervix, uterine: 618.9;kidney: 1500.2",salivary gland: 232.3,Cell line enhanced,,NB-4: 34.9;SCLC-21H: 45.7;THP-1: 129.4
30,DIO3,TXDI3,ENSG00000197406,Iodothyronine deiodinase 3,14,101561351-101563452,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,"cervix, uterine: 27.8;placenta: 25.4",ovary: 6.2,Cell line enriched,37.0,AF22: 53.5
31,DKK1,"DKK-1, SK",ENSG00000107984,Dickkopf WNT signaling pathway inhibitor 1,10,52314296-52318042,Predicted secreted proteins,Evidence at protein level,,,,,,"Head and neck cancer:4.35e-8 (unfavourable), Lung cancer:7.80e-6 (unfavourable), Pancreatic cancer:1.27e-4 (unfavourable)",Mixed,Tissue enhanced,,"cervix, uterine: 56.5;placenta: 71.9",urinary bladder: 14.5,Cell line enhanced,,BJ: 975.2;CACO-2: 841.6;fHDF/TERT166: 1247.0
32,DKK2,,ENSG00000155011,Dickkopf WNT signaling pathway inhibitor 2,4,106921802-107283806,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB009727, HPA052611",Uncertain,,Supported,Golgi apparatus,,Mixed,Tissue enhanced,,"cervix, uterine: 24.1",lung: 8.2,Cell line enriched,7.0,SH-SY5Y: 23.5
33,ENPP3,"B10, CD203c, gp130RB13-6, PD-IBETA, PDNP3",ENSG00000154269,Ectonucleotide pyrophosphatase/phosphodiesterase 3,6,131628442-131747418,"CD markers, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA043772,Enhanced,,,,Renal cancer:1.96e-4 (unfavourable),Tissue enriched,Tissue enhanced,,"cervix, uterine: 45.4;small intestine: 49.9",seminal vesicle: 22.0,Group enriched,15.0,HEL: 3.9;Hep G2: 9.9;HMC-1: 5.4
34,ENTPD3,"CD39L3, HB6, NTPDase-3",ENSG00000168032,Ectonucleoside triphosphate diphosphohydrolase 3,3,40387156-40428619,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA071802,,,Approved,Cytosol,,Mixed,Tissue enhanced,,"cervix, uterine: 33.6",urinary bladder: 14.7,Cell line enhanced,,HBEC3-KT: 9.3;hTCEpi: 6.3;RT4: 15.1
35,EPO,EP,ENSG00000130427,Erythropoietin,7,100720800-100723700,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Predicted secreted proteins",Evidence at protein level,CAB010336,Supported,,,,"Renal cancer:2.18e-6 (unfavourable), Liver cancer:5.67e-5 (unfavourable)",Group enriched,Tissue enhanced,,"cervix, uterine: 2.0;endometrium: 1.7;liver: 1.7",prostate: 1.1,Group enriched,6.0,BEWO: 2.0;Hep G2: 5.5
36,EYA2,EAB1,ENSG00000064655,EYA transcriptional coactivator and phosphatase 2,20,46894624-47188844,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA027024, HPA059291",Uncertain,,Supported,Cytosol,Endometrial cancer:4.30e-5 (favourable),Tissue enhanced,Tissue enhanced,,"cervix, uterine: 76.3",fallopian tube: 50.0,Cell line enhanced,,HBEC3-KT: 28.0;SCLC-21H: 68.4;U-266/70: 82.5;U-266/84: 98.8
37,FGF14,"FHF4, SCA27",ENSG00000102466,Fibroblast growth factor 14,13,101710804-102402457,"Disease related genes, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA049828,,,Approved,Nucleoli fibrillar center,,Tissue enhanced,Tissue enhanced,,"cerebral cortex: 14.8;cervix, uterine: 22.9;fallopian tube: 17.2",testis: 4.3,Group enriched,7.0,SCLC-21H: 5.4;SH-SY5Y: 20.7;U-87 MG: 4.1
38,FOLR1,FOLR,ENSG00000110195,Folate receptor 1,11,72189558-72196323,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA077030,,,Approved,Nuclear membrane,Liver cancer:2.50e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,"cervix, uterine: 166.6;fallopian tube: 275.8;lung: 267.5",kidney: 152.7,Group enriched,6.0,HeLa: 298.2;RPTEC TERT1: 350.8
39,FOXA2,HNF3B,ENSG00000125798,Forkhead box A2,20,22581005-22585455,"Cancer-related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB001388, HPA066846",Enhanced,,Supported,Nucleoplasm<br>Cell Junctions,"Endometrial cancer:7.57e-6 (favourable), Pancreatic cancer:2.34e-4 (favourable), Ovarian cancer:6.28e-4 (favourable)",Mixed,Tissue enhanced,,"cervix, uterine: 21.4;lung: 20.5;stomach: 31.0",liver: 11.5,Cell line enhanced,,A549: 16.1;HBEC3-KT: 14.5;Hep G2: 19.5;PC-3: 24.0;SCLC-21H: 52.3
40,FOXI2,FLJ46831,ENSG00000186766,Forkhead box I2,10,127737235-127741186,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,,,,,,Renal cancer:4.23e-7 (favourable),Tissue enriched,Tissue enhanced,,"cervix, uterine: 2.6",kidney: 1.6,Not detected,,
41,FZD10,CD350,ENSG00000111432,Frizzled class receptor 10,12,130162459-130165740,"CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA014484, HPA014485",Uncertain,,Supported,Nucleoplasm,Endometrial cancer:5.05e-7 (favourable),Mixed,Tissue enhanced,,"cervix, uterine: 9.4;esophagus: 8.8",skin: 5.6,Cell line enhanced,,AF22: 5.4;BEWO: 6.1;hTCEpi: 2.6;RT4: 2.5
42,GABRQ,THETA,ENSG00000268089,Gamma-aminobutyric acid type A receptor theta subunit,X,152638183-152657534,"FDA approved drug targets, Predicted membrane proteins",Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,"cerebral cortex: 6.6;cervix, uterine: 12.9",adrenal gland: 3.0,Group enriched,7.0,HeLa: 8.2;SiHa: 12.7;U-87 MG: 37.4
43,GLI1,GLI,ENSG00000111087,GLI family zinc finger 1,12,57460135-57472262,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB009460, HPA065172, HPA068903",Uncertain,,Enhanced,Nucleoplasm<br>Cytosol,,Tissue enhanced,Tissue enhanced,,"cervix, uterine: 15.1;endometrium: 15.1",gallbladder: 8.5,Cell line enhanced,,AN3-CA: 19.3;RH-30: 59.1
44,HOXA13,"HOX1, HOX1J",ENSG00000106031,Homeobox A13,7,27193503-27200106,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,"cervix, uterine: 34.0;placenta: 24.5;prostate: 36.2;seminal vesicle: 32.5",rectum: 13.0,Cell line enhanced,,HAP1: 27.6;HEK93: 34.0;RT4: 33.4
45,HPSE2,"HPA2, HPR2, UFS",ENSG00000172987,Heparanase 2 (inactive),10,98457077-99235862,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA044603,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,"cervix, uterine: 53.4",prostate: 22.8,Group enriched,24.0,BJ hTERT+: 11.3;HEL: 23.9
46,HTR2B,"5-HT(2B), 5-HT2B",ENSG00000135914,5-hydroxytryptamine receptor 2B,2,231108230-231125118,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA012867, HPA063658",Enhanced,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,"cervix, uterine: 31.2;endometrium: 30.1;smooth muscle: 23.2",adrenal gland: 19.1,Cell line enhanced,,HHSteC: 7.0;HSkMC: 11.5;SK-MEL-30: 23.9
47,IBSP,"BSP, BSP-II, SP-II",ENSG00000029559,Integrin binding sialoprotein,4,87799581-87812435,"Cancer-related genes, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,"cerebral cortex: 1.6;cervix, uterine: 1.3","gallbladder,placenta: 0.3",Cell line enriched,6.0,U-138 MG: 7.3
48,IGF1,"IGF-I, IGF1A, IGFI",ENSG00000017427,Insulin like growth factor 1,12,102395867-102480645,"Disease related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,HPA048946,Approved,,,,Endometrial cancer:1.04e-4 (favourable),Mixed,Tissue enhanced,,"cervix, uterine: 126.8",smooth muscle: 98.2,Cell line enhanced,,ASC diff: 21.1;HDLM-2: 45.4;K-562: 19.8;U-266/70: 10.2
49,IGFBP5,,ENSG00000115461,Insulin like growth factor binding protein 5,2,216672105-216695525,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA059827,,,Approved,Nuclear bodies<br>Golgi apparatus<br>Vesicles,Endometrial cancer:1.78e-4 (unfavourable),Expressed in all,Tissue enhanced,,"cervix, uterine: 2374.4;ovary: 1646.3",fallopian tube: 949.1,Cell line enhanced,,BJ: 704.3;BJ hTERT+: 1787.5;T-47d: 500.8;U-138 MG: 702.9
50,ITGA11,HsT18964,ENSG00000137809,Integrin subunit alpha 11,15,68296533-68432162,Predicted membrane proteins,Evidence at protein level,HPA051813,Uncertain,,,,Renal cancer:3.22e-7 (unfavourable),Mixed,Tissue enhanced,,"cervix, uterine: 54.7;endometrium: 52.4;smooth muscle: 75.7",epididymis: 22.9,Cell line enhanced,,fHDF/TERT166: 203.4;U-138 MG: 173.0;WM-115: 98.4
51,LTF,HLF2,ENSG00000012223,Lactotransferrin,3,46435645-46485234,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB008646, CAB016201, HPA057177, HPA059976",Enhanced,,,,Renal cancer:6.30e-5 (favourable),Expressed in all,Tissue enhanced,,"bone marrow: 2804.3;cervix, uterine: 1030.7",seminal vesicle: 532.6,Group enriched,10.0,RPMI-8226: 28.9;TIME: 11.6
52,MAML1,"KIAA0200, Mam-1",ENSG00000161021,Mastermind like transcriptional coactivator 1,5,179732850-179796511,Predicted intracellular proteins,Evidence at protein level,"HPA037687, HPA057531",Approved,,Enhanced,Nucleoplasm,"Renal cancer:1.84e-5 (unfavourable), Melanoma:9.70e-4 (unfavourable)",Expressed in all,Tissue enhanced,,"cervix, uterine: 15.3",small intestine: 8.5,Cell line enhanced,,SK-MEL-30: 15.6
53,MAS1L,"dJ994E9.2, MAS-L, MRG",ENSG00000204687,"MAS1 proto-oncogene like, G protein-coupled receptor",6,29486697-29487956,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,HPA017983,Uncertain,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,,Not detected,Tissue enhanced,,"cervix, uterine: 5.1",epididymis: 2.3,Not detected,,
54,MASP1,"CRARF, MASP, PRSS5",ENSG00000127241,Mannan binding lectin serine peptidase 1,3,187217285-187292022,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA001617, HPA009641",Supported,,Supported,Nucleoplasm<br>Cytosol,Liver cancer:2.20e-4 (favourable),Group enriched,Tissue enhanced,,"cervix, uterine: 135.4",endometrium: 94.8,Group enriched,8.0,BJ: 107.2;BJ hTERT+: 389.0
55,MITF,"bHLHe32, MI, WS2, WS2A",ENSG00000187098,Melanogenesis associated transcription factor,3,69739435-69968337,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB002578, HPA003259",Enhanced,,,,Renal cancer:8.35e-10 (favourable),Group enriched,Tissue enhanced,,"cervix, uterine: 80.9;endometrium: 79.3",smooth muscle: 69.5,Cell line enhanced,,HMC-1: 78.7;SK-MEL-30: 205.7
56,MPPED2,"239FB, C11orf8, D11S302E, dJ1024C24.1, dJ873F21.1, FAM1B, Hs.46638",ENSG00000066382,Metallophosphoesterase domain containing 2,11,30384493-30586872,Predicted intracellular proteins,Evidence at protein level,HPA062575,,,Approved,Nucleoli<br>Vesicles<br>Mitochondria,,Mixed,Tissue enhanced,,"cervix, uterine: 38.7;thyroid gland: 43.7",prostate: 20.9,Cell line enhanced,,HaCaT: 19.2;HAP1: 13.2;RT4: 7.3;SH-SY5Y: 7.2
57,MRGPRE,"GPR167, mrgE",ENSG00000184350,MAS related GPR family member E,11,3227698-3232386,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,HPA046556,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,"cervix, uterine: 1.0",endometrium: 0.7,Cell line enhanced,,RPMI-8226: 1.5;SCLC-21H: 4.1
58,MUC16,"CA125, FLJ14303",ENSG00000181143,"Mucin 16, cell surface associated",19,8848844-8981342,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB055172, HPA065600",Enhanced,,,,,Tissue enhanced,Tissue enhanced,,"cervix, uterine: 24.0;fallopian tube: 9.4",endometrium: 3.5,Cell line enhanced,,A-431: 20.2;CAPAN-2: 7.0;HaCaT: 6.8;HeLa: 26.2
59,MXRA5,DKFZp564I1922,ENSG00000101825,Matrix remodeling associated 5,X,3308565-3346641,"Cancer-related genes, Disease related genes, Predicted secreted proteins",Evidence at protein level,HPA000508,Uncertain,,Uncertain,Mitochondria,"Glioma:2.56e-4 (unfavourable), Urothelial cancer:8.94e-4 (unfavourable)",Expressed in all,Tissue enhanced,,"cervix, uterine: 57.1",skin: 35.2,Cell line enhanced,,BJ hTERT+: 102.1;fHDF/TERT166: 46.4;HaCaT: 46.3
60,NT5E,"CALJA, CD73, eN, eNT, NT5",ENSG00000135318,5'-nucleotidase ecto,6,85449584-85495791,"CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA017357,Approved,,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Pancreatic cancer:1.32e-5 (unfavourable), Stomach cancer:1.02e-4 (unfavourable), Lung cancer:6.66e-4 (unfavourable)",Expressed in all,Tissue enhanced,,"cervix, uterine: 172.7",smooth muscle: 106.3,Cell line enhanced,,LHCN-M2: 772.3;U-87 MG: 800.0
61,OGN,"mimecan, OIF, SLRR3A",ENSG00000106809,Osteoglycin,9,92383967-92404696,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA013132,Approved,,Supported,Endoplasmic reticulum,"Renal cancer:1.92e-4 (unfavourable), Urothelial cancer:2.03e-4 (unfavourable), Ovarian cancer:4.04e-4 (unfavourable)",Mixed,Tissue enhanced,,"cervix, uterine: 374.3;parathyroid gland: 604.4",gallbladder: 276.4,Cell line enhanced,,ASC TERT1: 17.1;HSkMC: 8.0;MOLT-4: 27.9
62,PAMR1,"DKFZP586H2123, RAMP",ENSG00000149090,Peptidase domain containing associated with muscle regeneration 1,11,35431823-35530300,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,"Renal cancer:5.08e-5 (unfavourable), Stomach cancer:6.29e-4 (unfavourable)",Expressed in all,Tissue enhanced,,"cervix, uterine: 87.0;endometrium: 92.2",placenta: 76.1,Cell line enhanced,,ASC TERT1: 233.7;BJ hTERT+: 274.9;HSkMC: 84.2;U-87 MG: 78.6
63,PCOLCE,"PCPE, PCPE1",ENSG00000106333,Procollagen C-endopeptidase enhancer,7,100602177-100608175,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB017623, HPA042927",Approved,,Approved,Golgi apparatus<br>Vesicles,"Renal cancer:1.68e-5 (unfavourable), Melanoma:9.76e-4 (unfavourable)",Expressed in all,Tissue enhanced,,"cervix, uterine: 216.8",gallbladder: 145.9,Cell line enhanced,,ASC TERT1: 496.8;BJ hTERT+: 447.9;HSkMC: 595.6;SH-SY5Y: 617.5;U-2197: 961.3
64,PGBD5,"DKFZp761A0620, FLJ11413",ENSG00000177614,PiggyBac transposable element derived 5,1,230314482-230426371,Predicted intracellular proteins,Evidence at protein level,HPA065010,,,Approved,Nucleoplasm,Glioma:1.20e-4 (unfavourable),Mixed,Tissue enhanced,,"cerebral cortex: 40.1;cervix, uterine: 29.1",adrenal gland: 12.6,Cell line enhanced,,Daudi: 21.9;NTERA-2: 30.2;RH-30: 15.9;SCLC-21H: 48.7
65,PHF21B,"BHC80L, FLJ34161, PHF4",ENSG00000056487,PHD finger protein 21B,22,44881162-45009999,Predicted intracellular proteins,Evidence at protein level,HPA053834,Uncertain,,Uncertain,Nucleus<br>Nucleoli fibrillar center,,Tissue enhanced,Tissue enhanced,,"cerebral cortex: 6.7;cervix, uterine: 5.5;testis: 6.4",endometrium: 5.4,Cell line enhanced,,AF22: 11.1;AN3-CA: 9.4;SCLC-21H: 10.3;SH-SY5Y: 41.0;U-2 OS: 9.1
66,PI16,"CD364, dJ90K10.5, MGC45378, MSMBBP",ENSG00000164530,Peptidase inhibitor 16,6,36948263-36964837,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA076574,Approved,,,,,Tissue enhanced,Tissue enhanced,,"cervix, uterine: 199.5",urinary bladder: 78.6,Cell line enhanced,,Daudi: 3.7;fHDF/TERT166: 3.6;U-2197: 1.0
67,PLEKHS1,"bA211N11.2, C10orf81, FLJ23537",ENSG00000148735,Pleckstrin homology domain containing S1,10,113751454-113783429,Predicted intracellular proteins,Evidence at protein level,HPA037583,,,Supported,Centrosome,Urothelial cancer:1.03e-4 (favourable),Mixed,Tissue enhanced,,"cervix, uterine: 88.6",duodenum: 41.1,Cell line enhanced,,CAPAN-2: 7.3;RH-30: 3.8;RT4: 12.5;T-47d: 4.9
68,PLK5,"PLK5P, SgK384ps",ENSG00000185988,Polo like kinase 5,19,1524074-1535456,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA035024,Enhanced,,,,,Mixed,Tissue enhanced,,"cervix, uterine: 4.5;endometrium: 4.7;testis: 6.9",epididymis: 3.3,Not detected,,
69,PLXNA4,"DKFZp434G0625PRO34003, FAYV2820, KIAA1550, PLXNA4A, PLXNA4B",ENSG00000221866,Plexin A4,7,132123332-132648688,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA029919, HPA052141, HPA075592",Approved,,Approved,Plasma membrane,Endometrial cancer:1.61e-6 (unfavourable),Tissue enhanced,Tissue enhanced,,"adipose tissue: 15.2;cervix, uterine: 12.5",cerebral cortex: 10.4,Cell line enhanced,,ASC diff: 17.3;HMC-1: 15.0;RH-30: 17.9;TIME: 46.9
70,PMEPA1,"STAG1, TMEPAI",ENSG00000124225,"Prostate transmembrane protein, androgen induced 1",20,57648392-57711536,"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA072291,,,Supported,Vesicles,"Renal cancer:2.87e-7 (unfavourable), Lung cancer:4.73e-5 (unfavourable), Cervical cancer:2.45e-4 (unfavourable), Urothelial cancer:7.60e-4 (unfavourable)",Expressed in all,Tissue enhanced,,"cervix, uterine: 146.1;prostate: 179.6",endometrium: 60.3,Cell line enhanced,,SiHa: 218.5;U-251 MG: 397.1;WM-115: 233.9
71,PROM1,"AC133, CD133, CORD12, MCDR2, PROML1, RP41, STGD4",ENSG00000007062,Prominin 1,4,15963076-16084378,"CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA004922, CAB011525, HPA031053",Enhanced,,,,Renal cancer:2.56e-5 (favourable),Expressed in all,Tissue enhanced,,"cervix, uterine: 67.2",gallbladder: 47.5,Cell line enhanced,,AF22: 36.7;CACO-2: 58.5;EFO-21: 62.9;NTERA-2: 99.9;RPTEC TERT1: 69.7
72,PRR15,,ENSG00000176532,Proline rich 15,7,29563811-29567295,Predicted intracellular proteins,Evidence at protein level,"HPA040996, HPA048121",Enhanced,,Uncertain,Vesicles<br>Cell Junctions,"Renal cancer:1.83e-6 (favourable), Endometrial cancer:6.37e-4 (favourable), Lung cancer:7.23e-4 (unfavourable)",Mixed,Tissue enhanced,,"cervix, uterine: 91.4",colon: 79.1,Cell line enhanced,,CAPAN-2: 33.6;HaCaT: 39.3;SK-BR-3: 55.3
73,PRRX2,"PMX2, PRX2",ENSG00000167157,Paired related homeobox 2,9,129665641-129722674,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,"HPA006607, HPA026808",Approved,,Approved,Nucleoplasm<br>Nuclear bodies,,Mixed,Tissue enhanced,,"cervix, uterine: 9.9;skin: 10.7",testis: 6.3,Cell line enhanced,,BJ: 24.1;BJ hTERT+: 16.5;fHDF/TERT166: 32.1;U-2197: 31.5
74,PTCH1,"BCNS, NBCCS, PTCH",ENSG00000185920,Patched 1,9,95442980-95517057,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB013717, HPA075072",Uncertain,,Approved,Golgi apparatus,,Mixed,Tissue enhanced,,"cervix, uterine: 41.7",endometrium: 27.2,Cell line enhanced,,WM-115: 70.2
75,RORB,"NR1F2, ROR-BETA, RZRB",ENSG00000198963,RAR related orphan receptor B,9,74497365-74693177,"Nuclear receptors, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA008393,Uncertain,,Approved,Nucleus,,Group enriched,Tissue enhanced,,"cerebral cortex: 12.6;cervix, uterine: 14.1",prostate: 7.4,Cell line enhanced,,HHSteC: 18.9;HSkMC: 9.0;MOLT-4: 5.5;SH-SY5Y: 14.3
76,RP3-454G6.2,,ENSG00000283683,,1,171600621-171638799,Predicted intracellular proteins,Evidence at transcript level,,,,,,,,Tissue enhanced,,"cervix, uterine: 8.0;fallopian tube: 4.6",epididymis: 4.1,Cell line enriched,6.0,HEL: 24.8
77,SAA2,,ENSG00000134339,Serum amyloid A2,11,18239223-18248643,"Disease related genes, Predicted secreted proteins",Evidence at protein level,,,,,,Renal cancer:1.30e-8 (unfavourable),Tissue enriched,Tissue enhanced,,"adipose tissue: 713.3;cervix, uterine: 414.7;liver: 581.2",appendix: 211.6,Cell line enhanced,,A-431: 25.4;EFO-21: 20.0;HaCaT: 23.6;HBEC3-KT: 41.5
78,SAA2-SAA4,,ENSG00000255071,SAA2-SAA4 readthrough,11,18231423-18248635,Predicted membrane proteins,Evidence at transcript level,HPA060139,Uncertain,,,,"Renal cancer:2.92e-8 (unfavourable), Breast cancer:4.56e-4 (favourable), Glioma:9.87e-4 (unfavourable)",Tissue enriched,Tissue enhanced,,"adipose tissue: 27.9;cervix, uterine: 22.6;liver: 15.0",breast: 5.4,Cell line enhanced,,A-431: 2.3;EFO-21: 1.4
79,SCGB1D1,"LIPA, LPHA, MGC71958",ENSG00000168515,Secretoglobin family 1D member 1,11,62190216-62193539,Predicted secreted proteins,Evidence at protein level,,,,,,,Group enriched,Tissue enhanced,,"cervix, uterine: 2.0;fallopian tube: 1.3",endometrium: 0.5,Cell line enriched,43.0,SCLC-21H: 7.1
80,SCNN1B,ENaCbeta,ENSG00000168447,Sodium channel epithelial 1 beta subunit,16,23278231-23381299,"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA015612,Uncertain,,,,Renal cancer:2.09e-6 (unfavourable),Tissue enhanced,Tissue enhanced,,"cervix, uterine: 72.0",esophagus: 44.8,Cell line enhanced,,hTCEpi: 24.0;RT4: 14.6;U-266/70: 41.7;U-266/84: 14.3
81,SCNN1G,"ENaCgamma, SCNEG",ENSG00000166828,Sodium channel epithelial 1 gamma subunit,16,23182715-23216883,"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA071194,,,Supported,Nucleoplasm<br>Plasma membrane,Renal cancer:3.20e-7 (unfavourable),Tissue enhanced,Tissue enhanced,,"cervix, uterine: 24.6;kidney: 46.7",thyroid gland: 9.5,Group enriched,5.0,hTCEpi: 33.4;RT4: 17.1
82,SDK1,FLJ31425,ENSG00000146555,Sidekick cell adhesion molecule 1,7,3301448-4269000,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA011392,Approved,,Approved,Cytosol,Pancreatic cancer:4.08e-4 (favourable),Mixed,Tissue enhanced,,"cervix, uterine: 15.0",spleen: 6.0,Cell line enhanced,,BEWO: 10.1;RT4: 8.9;U-2 OS: 13.6
83,SDK2,"FLJ10832, KIAA1514",ENSG00000069188,Sidekick cell adhesion molecule 2,17,73334384-73644089,Predicted membrane proteins,Evidence at protein level,HPA014725,,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,"cervix, uterine: 9.0;testis: 18.6",fallopian tube: 4.0,Cell line enhanced,,AF22: 13.8;BEWO: 11.0;U-2 OS: 5.0
84,SFRP1,"FRP, FRP-1, SARP2",ENSG00000104332,Secreted frizzled related protein 1,8,41261958-41309497,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB008116, HPA064870",Approved,,Approved,Nucleoli<br>Cytosol,"Head and neck cancer:1.55e-4 (favourable), Urothelial cancer:3.12e-4 (unfavourable)",Mixed,Tissue enhanced,,"breast: 357.2;cervix, uterine: 325.0",endometrium: 231.0,Cell line enhanced,,BJ hTERT+: 563.8;HBF TERT88: 268.7;RPTEC TERT1: 319.1;WM-115: 275.2
85,SHISA6,FLJ45455,ENSG00000188803,Shisa family member 6,17,11241263-11564063,"Predicted membrane proteins, Transporters",Evidence at transcript level,HPA023440,Uncertain,,,,,Mixed,Tissue enhanced,,"cervix, uterine: 24.7",seminal vesicle: 10.2,Cell line enriched,8.0,NTERA-2: 2.2
86,SLC15A2,PEPT2,ENSG00000163406,Solute carrier family 15 member 2,3,121894089-121944102,"Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,"Cervical cancer:2.37e-4 (favourable), Lung cancer:6.74e-4 (favourable), Endometrial cancer:6.96e-4 (favourable)",Mixed,Tissue enhanced,,"cervix, uterine: 78.5;prostate: 64.9",epididymis: 47.8,Mixed,,
87,SLC18A2,"SVAT, SVMT, VMAT2",ENSG00000165646,Solute carrier family 18 member A2,10,117241093-117279430,"FDA approved drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA073224,Approved,,,,,Mixed,Tissue enhanced,,"cervix, uterine: 47.6",adrenal gland: 19.0,Cell line enriched,18.0,HMC-1: 308.7
88,SLC51B,OSTbeta,ENSG00000186198,Solute carrier family 51 beta subunit,15,65045370-65053396,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA008398, HPA008533",Enhanced,,Approved,Vesicles<br>Mitochondria,Renal cancer:8.46e-5 (favourable),Tissue enhanced,Tissue enhanced,,"cervix, uterine: 59.7;duodenum: 85.4;small intestine: 118.4",colon: 40.7,Group enriched,9.0,CACO-2: 15.0;EFO-21: 11.0;Hep G2: 10.4
89,SLC5A8,AIT,ENSG00000256870,Solute carrier family 5 member 8,12,101155493-101210407,Predicted membrane proteins,Evidence at protein level,,,,,,"Breast cancer:9.04e-6 (favourable), Renal cancer:1.97e-4 (favourable)",Tissue enhanced,Tissue enhanced,,"cervix, uterine: 15.0;thyroid gland: 14.7",kidney: 3.5,Cell line enriched,6.0,SK-BR-3: 2.3
90,SLC6A14,,ENSG00000268104,Solute carrier family 6 member 14,X,116436622-116461458,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at transcript level,HPA003193,Uncertain,,Approved,Vesicles,Pancreatic cancer:9.74e-4 (unfavourable),Mixed,Tissue enhanced,,"cervix, uterine: 11.0;lung: 23.9",breast: 9.1,Cell line enhanced,,HeLa: 1.0;Hep G2: 2.3
91,SMCO3,"C12orf69, LOC440087",ENSG00000179256,Single-pass membrane protein with coiled-coil domains 3,12,14804650-14814182,Predicted membrane proteins,Evidence at protein level,"HPA040574, HPA047804",Uncertain,,,,,Tissue enhanced,Tissue enhanced,,"cervix, uterine: 5.6","gallbladder,kidney: 3.0",Cell line enhanced,,AN3-CA: 1.8
92,SOX17,,ENSG00000164736,SRY-box 17,8,54457935-54460888,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB025594, HPA068399",Enhanced,,Approved,Nucleoplasm,Endometrial cancer:2.76e-4 (favourable),Group enriched,Tissue enhanced,,"cervix, uterine: 30.2;endometrium: 32.2;fallopian tube: 30.1",adipose tissue: 14.7,Cell line enriched,8.0,EFO-21: 102.6
93,STC1,STC,ENSG00000159167,Stanniocalcin 1,8,23841915-23854807,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB018625, HPA023918",Approved,,,,"Renal cancer:1.23e-6 (unfavourable), Glioma:9.44e-5 (unfavourable), Lung cancer:1.53e-4 (unfavourable), Stomach cancer:5.55e-4 (unfavourable), Head and neck cancer:6.32e-4 (unfavourable), Cervical cancer:8.45e-4 (unfavourable)",Expressed in all,Tissue enhanced,,"cervix, uterine: 78.0",endometrium: 53.9,Cell line enhanced,,BJ hTERT+: 280.7;hTEC/SVTERT24-B: 201.5;U-87 MG: 608.6
94,STRA6,FLJ12541,ENSG00000137868,Stimulated by retinoic acid 6,15,74179466-74212267,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA040839,Approved,,Approved,Nucleus<br>Cytosol,,Mixed,Tissue enhanced,,"cervix, uterine: 37.0;placenta: 20.4",endometrium: 13.2,Cell line enhanced,,CAPAN-2: 162.1;SH-SY5Y: 119.5;WM-115: 273.5
95,TACR1,"NK1R, NKIR, SPR, TAC1R",ENSG00000115353,Tachykinin receptor 1,2,75046463-75199700,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA074573,Enhanced,,,,,Mixed,Tissue enhanced,,"cervix, uterine: 7.3",fallopian tube: 4.7,Not detected,,
96,TFF3,"HITF, ITF",ENSG00000160180,Trefoil factor 3,21,42311667-42315651,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB020681, HPA035464",Enhanced,,Approved,Nucleus<br>Nucleoli,Endometrial cancer:5.60e-6 (favourable),Expressed in all,Tissue enhanced,,"cervix, uterine: 470.7;colon: 496.2;rectum: 504.3;thyroid gland: 620.1",small intestine: 457.0,Cell line enhanced,,MCF7: 63.2;SCLC-21H: 28.3;T-47d: 35.0;TIME: 85.5
97,TGM2,TGC,ENSG00000198959,Transglutaminase 2,20,38127387-38166578,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB002598, HPA021019, HPA029518",Enhanced,,Approved,Plasma membrane<br>Cytosol,"Renal cancer:1.67e-7 (unfavourable), Pancreatic cancer:2.97e-4 (unfavourable)",Expressed in all,Tissue enhanced,,"cervix, uterine: 461.0",placenta: 319.8,Cell line enhanced,,CAPAN-2: 1300.3;EFO-21: 458.7;HUVEC TERT2: 559.8;TIME: 720.5
98,THSD4,"ADAMTSL6, FLJ13710, FVSY9334, PRO34005",ENSG00000187720,Thrombospondin type 1 domain containing 4,15,71096952-71783383,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA026845,,,Approved,Nucleus<br>Nucleoli,,Mixed,Tissue enhanced,,"cervix, uterine: 160.5",fallopian tube: 59.6,Cell line enhanced,,BJ hTERT+: 43.1;TIME: 54.2
99,TMC1,"DFNA36, DFNB11, DFNB7",ENSG00000165091,Transmembrane channel like 1,9,72521801-72836351,"Disease related genes, Predicted membrane proteins",Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,"cervix, uterine: 1.6",placenta: 1.0,Cell line enhanced,,BEWO: 3.1;HAP1: 6.7;NTERA-2: 3.0;U-266/70: 1.6;U-266/84: 1.5
100,TMEM119,,ENSG00000183160,Transmembrane protein 119,12,108589846-108598320,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA051870, HPA052650",Enhanced,,,,"Renal cancer:2.06e-6 (unfavourable), Ovarian cancer:8.37e-4 (unfavourable)",Expressed in all,Tissue enhanced,,"cervix, uterine: 93.0",gallbladder: 55.2,Cell line enhanced,,ASC diff: 378.8;ASC TERT1: 106.4;BJ hTERT+: 134.8;HSkMC: 171.1
101,TMEM132C,"DKFZp761O2018, PPP1R152",ENSG00000181234,Transmembrane protein 132C,12,128267403-128707915,Predicted membrane proteins,Evidence at protein level,"HPA015633, HPA015984",,,Supported,Centrosome<br>Cytosol,,Tissue enhanced,Tissue enhanced,,"adipose tissue: 34.8;cervix, uterine: 24.1",fallopian tube: 15.9,Group enriched,5.0,AF22: 3.7;ASC diff: 3.5;Daudi: 4.4
102,TMEM211,bA9F11.1,ENSG00000206069,Transmembrane protein 211,22,24934954-24946695,Predicted membrane proteins,Evidence at transcript level,HPA066784,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,"cervix, uterine: 3.7;stomach: 2.7",salivary gland: 1.4,Not detected,,
103,TMEM260,"C14orf101, FLJ20392",ENSG00000070269,Transmembrane protein 260,14,56488354-56650606,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA003502,Uncertain,,Approved,Nucleus<br>Focal adhesion sites<br>Cytosol,Lung cancer:7.11e-4 (favourable),Expressed in all,Tissue enhanced,,"cervix, uterine: 63.5",thyroid gland: 14.1,Expressed in all,,
104,TWIST2,"bHLHa39, Dermo-1, DERMO1",ENSG00000233608,Twist family bHLH transcription factor 2,2,238848032-238910543,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA062870,,,Supported,Nucleus<br>Nucleoli,,Mixed,Tissue enhanced,,"cervix, uterine: 40.1",adipose tissue: 27.3,Cell line enhanced,,ASC diff: 104.1;BJ: 108.5;BJ hTERT+: 326.5;fHDF/TERT166: 143.5;U-2197: 143.4
105,WISP2,"CCN5, CT58, CTGF-L",ENSG00000064205,WNT1 inducible signaling pathway protein 2,20,44714844-44728509,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,CAB019273,Approved,,,,,Tissue enhanced,Tissue enhanced,,"cervix, uterine: 459.5;ovary: 167.2",breast: 70.0,Cell line enhanced,,ASC TERT1: 71.5;HeLa: 40.1;U-2197: 313.4
106,XKR5,,ENSG00000275591,XK related 5,8,6808517-6835644,Predicted membrane proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,"cervix, uterine: 1.0",testis: 0.6,Cell line enhanced,,AF22: 3.0;NTERA-2: 1.9;SCLC-21H: 1.8;SH-SY5Y: 3.6
